Selectivity of δ- and κ-opioid ligands depends on the route of central administration in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 166-171

  Lunzer, Mary M ^a   Portoghese, Philip S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BENZYLIDENE DERIVATIVE; BENZYLIDENENALTREXONE; BREMAZOCINE; DELTORPHIN; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; NALTRIBEN; NALTRINDOLE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG SELECTIVITY; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; BENZYLIDENE COMPOUNDS; ENKEPHALIN, D-PENICILLAMINE (2,5)-; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; LIGANDS; MALE; MICE; MICE, INBRED ICR; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA;

EID: 34250775006     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120279     Document Type: Article

References (27)

1. 2 phenotypes. Selective targeting of δ-κ heterodimers. J Med Chem 47:2969-2972.
2. Burlenger S, Stefano M, and Bouvier M (2005) Emerging role of homo- and heterodimerization in G-protein coupled receptors biosynthesis maturation. Trends Pharmacol Sci 26:131-137.
3. 1 opioid receptor phenotypes. J Med Chem 48:1713-1716.
4. Erspamer V, Melchiorri P, Falconieri-Erspamer G, Negri L, Corsi R, Severini C, Barra D, Simmaco M, and Kreil G (1989) Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. Proc Natl Acad Sci U S A 86:5188-5192.
5. Finney DJ (1964) Statistical Methods in Biological Assay, Hafner Publishing Co., New York.
6. George SR, Fan T, Xie X, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of μ- and δ-opioid receptors. J Biol Chem 275:26128-26135.
7. Haley TJ and McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12:12-15.
8. Horan P, de Costa BR, Rice KC, and Porreca F (1991) Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of κ opioid receptor multiplicity in mice. J Pharmacol Exp Ther 257:1154-1161.
9. Hylden JL and Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313-316.
10. 6]enkephalin and naltrindole 5′-isothiocyanate: evidence for δ receptor subtypes. J Pharmacol Exp Ther 257:1069-1075.
11. Jordan BA and Devi LA (1999) G Protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700.
12. Miyamoto Y, Portoghese PS, and Takemori AE (1993) Involvement of δ-2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther 264:1141-1145.
13. Milligan G (2004) G protein-coupled receptors: function and ligand pharmacology. Mol Pharmacol 66:1-7.
14. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI, Galligan JJ, and Burks TF (1983) Bis-penicillinamine enkephalins possess highly improved specificity toward δ opioid receptors. Proc Natl Acad Sci U S A 80:5871-5874.
15. 1 opioid receptor as a δ-κ heteromer in the mouse spinal cord. Eur J Pharmacol 467:233-234.
16. Portoghese PS, Sultana M, Nagase H, Lin CE, and Takemori AE (1991) Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine. J Med Chem 34:1292-1296.
17. Portoghese PS, Sultana M, Nagase H, and Takemori AE (1992) A highly selective delta-1 opioid receptor antagonist: (BNTX). Eur J Pharmacol 218:195-196.
18. Portoghese PS, Sultana M, and Takemori AE (1988) Naltrindole, a highly selective and potent nonpeptide δ opioid receptor antagonist. Eur J Pharmacol 146:185-186.
19. Prinster SC, Hague C, and Hall RA (2005) Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57:289-298.
20. 3H]-bremazocine binding in a single and combinatorial opioid receptor knock-out mice. Eur J Pharmacol 414:189-195.
21. Sofuoglu M, Portoghese PS, and Takemori AE (1991) Differential antagonism of δ opioid agonists by naltrindole (NTI) and its benzofuran analog (NTB) in mice: evidence for δ opioid receptor subtypes. J Pharmacol Exp Ther 257:676-680.
22. Szmuszkovicz J and Von Voigtlander PF (1982) Benzenacetamide amines: structurally novel non-μ opioids. J Med Chem 25:1125-1126.
23. Tallarida RJ (2000) Drug Synergism and Dose Effect Data Analysis, Chapman & Hall/CRC, New York.
24. Terrilon S and Bouvier M (2004) Roles of G-protein coupled receptor dimerization. EMBO Rep 5:30-34.
25. Tulunay FC and Takemori AE (1974) The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J Pharmacol Exp Ther 190:395-400.
26. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kosteuis E, Portoghese PS, and Whistler JL (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102:9050-9055.
27. Xie Z, Bhushan RG, Daniels DJ, and Portoghese PS (2005) Interaction of bivalent ligand KDN-21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 68:1079-1086.